ID

44448

Descrição

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT01432353

Link

https://clinicaltrials.gov/show/NCT01432353

Palavras-chave

Versões (1)
  1. 22/09/2021 22/09/2021 -
Titular dos direitos

Genentech, Inc.

Transferido a

22 de setembro de 2021

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Multiple Myeloma NCT01432353

Inglês

Eligibility Multiple Myeloma NCT01432353

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients; >/= 18 years of age
Descrição

Age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
eastern cooperative oncology group (ecog) performance status 0, 1, or 2
Descrição

ECOG performance status

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1520224
relapsed or refractory multiple myeloma for which no effective standard therapy exists
Descrição

Relapsed multiple myeloma | Refractory multiple myeloma

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1370446
UMLS CUI [2]
C0278620
one of the prior therapies must have included a proteosome inhibitor or an immunomodulatory drug
Descrição

Prior therapy with a proteasome inhibitor | Prior therapy with an immunomodulatory drug

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1443643
UMLS CUI [1,2]
C1514463
UMLS CUI [2,1]
C1963758
UMLS CUI [2,2]
C1514463
measurable disease as defined by protocol
Descrição

Measurable disease as defined by protocol

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C2348563
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior use of monoclonal antibody within 4 weeks before cycle 1, day 1
Descrição

Recent use of monoclonal antibody

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0003250
UMLS CUI [1,2]
C0332185
treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any investigational anti-cancer agent within 2 weeks prior to cycle 1, day 1
Descrição

Recent Radiotherapy | Thalidomide | Lenalidomide | Bortezomib | Chemotheraphy | Any investigational anti-cancer agent

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0332185
UMLS CUI [2,1]
C0039736
UMLS CUI [2,2]
C0332185
UMLS CUI [3,1]
C1144149
UMLS CUI [3,2]
C0332185
UMLS CUI [4,1]
C1176309
UMLS CUI [4,2]
C0332185
UMLS CUI [5,1]
C0392920
UMLS CUI [5,2]
C0332185
UMLS CUI [6,1]
C0920425
UMLS CUI [6,2]
C0013230
UMLS CUI [6,3]
C0332185
toxicities from any previous treatment must be resolved prior to cycle 1, day 1, except for neuropathy
Descrição

Toxicities from any previous treatment (except neuropathy) must be resolved

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0600688
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C1514463
UMLS CUI [1,4]
C1514893
UMLS CUI [1,5]
C0442874
UMLS CUI [1,6]
C1705847
completion of autologous stem cell transplant within 100 days prior to cycle 1, day 1
Descrição

Transplantation of autologous hematopoietic stem cell

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1831743
prior allogeneic stem cell transplant
Descrição

Allogeneic Stem Cell Transplantation

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2242529
history of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
Descrição

History of severe allergic or anaphylactic reactions to monoclonal antibody therapy | History of severe allergic or anaphylactic reactions to recombinant antibody-related fusion proteins

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0003250
UMLS CUI [1,2]
C0020517
UMLS CUI [1,3]
C0205082
UMLS CUI [1,4]
C0262926
UMLS CUI [2,1]
C0003250
UMLS CUI [2,2]
C0002792
UMLS CUI [2,3]
C0205082
UMLS CUI [2,4]
C0262926
UMLS CUI [3,1]
C0003250
UMLS CUI [3,2]
C0034861
UMLS CUI [3,3]
C0020517
UMLS CUI [3,4]
C0205082
UMLS CUI [3,5]
C0262926
UMLS CUI [4,1]
C0003250
UMLS CUI [4,2]
C0034861
UMLS CUI [4,3]
C0002792
UMLS CUI [4,4]
C0205082
UMLS CUI [4,5]
C0262926
grade > 1 peripheral neuropathy
Descrição

Grade of peripheral neuropathy

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C0441800
active infection at screening or any major episode of infection requiring treatment with iv antibiotics or hospitalization within 4 weeks prior to cycle 1, day 1
Descrição

Active infection | Recent episode of an infection requiring treatment with iv antibiotics or hospitalization

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205177
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C1514873
UMLS CUI [2,3]
C0559680
UMLS CUI [2,4]
C0332185
UMLS CUI [3,1]
C0009450
UMLS CUI [3,2]
C1514873
UMLS CUI [3,3]
C0019993
UMLS CUI [3,4]
C0332185
positive for hepatitis b, hepatitis c or hiv infection
Descrição

Hepatitis B positive | Hepatitis C positive | HIV seropositivity

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0019163
UMLS CUI [1,2]
C1446409
UMLS CUI [2,1]
C0019196
UMLS CUI [2,2]
C1446409
UMLS CUI [3]
C0019699
pregnant or lactating women or women who intend to become pregnant within the period of time of this study
Descrição

Pregnancy | Breast Feeding | Pregnancy planned

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0032992
Voltar ao início da página

Similar models

Eligibility Multiple Myeloma NCT01432353

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
adult patients; >/= 18 years of age
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0, 1, or 2
boolean
C1520224 (UMLS CUI [1])
Relapsed multiple myeloma | Refractory multiple myeloma
Item
relapsed or refractory multiple myeloma for which no effective standard therapy exists
boolean
C1370446 (UMLS CUI [1])
C0278620 (UMLS CUI [2])
Prior therapy with a proteasome inhibitor | Prior therapy with an immunomodulatory drug
Item
one of the prior therapies must have included a proteosome inhibitor or an immunomodulatory drug
boolean
C1443643 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C1963758 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
Measurable disease as defined by protocol
Item
measurable disease as defined by protocol
boolean
C1513041 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Recent use of monoclonal antibody
Item
prior use of monoclonal antibody within 4 weeks before cycle 1, day 1
boolean
C0003250 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
Recent Radiotherapy | Thalidomide | Lenalidomide | Bortezomib | Chemotheraphy | Any investigational anti-cancer agent
Item
treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any investigational anti-cancer agent within 2 weeks prior to cycle 1, day 1
boolean
C1522449 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0039736 (UMLS CUI [2,1])
C0332185 (UMLS CUI [2,2])
C1144149 (UMLS CUI [3,1])
C0332185 (UMLS CUI [3,2])
C1176309 (UMLS CUI [4,1])
C0332185 (UMLS CUI [4,2])
C0392920 (UMLS CUI [5,1])
C0332185 (UMLS CUI [5,2])
C0920425 (UMLS CUI [6,1])
C0013230 (UMLS CUI [6,2])
C0332185 (UMLS CUI [6,3])
Toxicities from any previous treatment (except neuropathy) must be resolved
Item
toxicities from any previous treatment must be resolved prior to cycle 1, day 1, except for neuropathy
boolean
C0600688 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C1514893 (UMLS CUI [1,4])
C0442874 (UMLS CUI [1,5])
C1705847 (UMLS CUI [1,6])
Transplantation of autologous hematopoietic stem cell
Item
completion of autologous stem cell transplant within 100 days prior to cycle 1, day 1
boolean
C1831743 (UMLS CUI [1])
Allogeneic Stem Cell Transplantation
Item
prior allogeneic stem cell transplant
boolean
C2242529 (UMLS CUI [1])
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy | History of severe allergic or anaphylactic reactions to recombinant antibody-related fusion proteins
Item
history of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
boolean
C0003250 (UMLS CUI [1,1])
C0020517 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,3])
C0262926 (UMLS CUI [1,4])
C0003250 (UMLS CUI [2,1])
C0002792 (UMLS CUI [2,2])
C0205082 (UMLS CUI [2,3])
C0262926 (UMLS CUI [2,4])
C0003250 (UMLS CUI [3,1])
C0034861 (UMLS CUI [3,2])
C0020517 (UMLS CUI [3,3])
C0205082 (UMLS CUI [3,4])
C0262926 (UMLS CUI [3,5])
C0003250 (UMLS CUI [4,1])
C0034861 (UMLS CUI [4,2])
C0002792 (UMLS CUI [4,3])
C0205082 (UMLS CUI [4,4])
C0262926 (UMLS CUI [4,5])
Grade of peripheral neuropathy
Item
grade > 1 peripheral neuropathy
boolean
C0031117 (UMLS CUI [1,1])
C0441800 (UMLS CUI [1,2])
Active infection | Recent episode of an infection requiring treatment with iv antibiotics or hospitalization
Item
active infection at screening or any major episode of infection requiring treatment with iv antibiotics or hospitalization within 4 weeks prior to cycle 1, day 1
boolean
C0009450 (UMLS CUI [1,1])
C0205177 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0559680 (UMLS CUI [2,3])
C0332185 (UMLS CUI [2,4])
C0009450 (UMLS CUI [3,1])
C1514873 (UMLS CUI [3,2])
C0019993 (UMLS CUI [3,3])
C0332185 (UMLS CUI [3,4])
Hepatitis B positive | Hepatitis C positive | HIV seropositivity
Item
positive for hepatitis b, hepatitis c or hiv infection
boolean
C0019163 (UMLS CUI [1,1])
C1446409 (UMLS CUI [1,2])
C0019196 (UMLS CUI [2,1])
C1446409 (UMLS CUI [2,2])
C0019699 (UMLS CUI [3])
Pregnancy | Breast Feeding | Pregnancy planned
Item
pregnant or lactating women or women who intend to become pregnant within the period of time of this study
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032992 (UMLS CUI [3])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial